Drug intelligence / Profile preview

ANP1

Development stage: Preclinical
Lead developer: Lineage Cell Therapeutics
Modality: Stem Cell Therapies → Cell Therapies

Overview

ANP1, also known as ReSonance, is an auditory neuronal progenitor cell therapy developed by Lineage Cell Therapeutics. It is being advanced in preclinical development for the treatment of hearing loss and auditory neuropathy. The therapy involves the transplant of auditory neuronal cells, with initial proof-of-concept results demonstrating successful delivery, engraftment, and survival of ANP1 cells. Lineage Cell Therapeutics is collaborating with William Demant Invest (WDI), Eriksholm Research Centre, and the University of Michigan Kresge Hearing Research Institute on its development, with WDI funding up to $12 million in research costs to support activities leading to a potential IND/CTA filing.

Brand names: ReSonance
Other names: auditory neuronal progenitor cell therapy

Beyond the preview

Go deeper on ANP1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANP1.

Explore the full profile